News & Updates
Showing Pharmacy articles
Showing
Induction chemo followed by chemoradiotherapy bumps up survival in advanced cervical cancer
A short-course induction chemotherapy conducted prior to chemoradiotherapy appears to deliver significant survival boost in locally advanced cervical cancer, according to the phase III GCIG INTERLACE trial.
TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment
The clinical response or survival benefit derived by patients with advanced cutaneous melanoma from adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) does not wane even with prior antiprogrammed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) treatment, according to a study. TIL therapy also provides benefits in the second-line setting after anti-PD-(L)1 treatment.
Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients
In a real-world analysis evaluating four oral antiviral agents for the treatment of COVID-19, two ritonavir-based regimens fared better than molnupiravir and azvudine in reducing hospital stay among patients hospitalized for mild or moderate disease.
Second-line tislelizumab + anlotinib + chemo shows potential to improve ES-SCLC survival
A treatment regimen combining tislelizumab, anlotinib, and two cycles of irinotecan in the second-line setting demonstrates favourable efficacy and safety in patients with extensive-stage small cell lung cancer (ES-SCLC), according to the results of the single-arm phase II ESTAIL study.